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Abstract. SQSTM1 mutations, coding for the p62 protein, were identified as a monogenic cause of Paget disease of bone and of
amyotrophic lateral sclerosis. More recently, SQSTM1 mutations were identified in few families with frontotemporal dementia.
We report a new family carrying SQSTM1 mutation and presenting with a clinical phenotype of speech apraxia or atypical
behavioral disorders, associated with early visuo-contructional deficits. This study further supports the implication of SQSTM1
in frontotemporal dementia, and enlarges the phenotypic spectrum associated with SQSTM1 mutations.
Keywords: Amyotrophic lateral sclerosis, apraxia of speech, behavioral variant of FTD, frontotemporal lobar degeneration, non
fluent variant of primary progressive aphasia, p62, Paget disease of bone, progressive non-fluent aphasia, progressive supranuclear
palsy, SQSTM1
INTRODUCTION
Frontotemporal degeneration (FTD) defines a het-
erogeneous group of disorders that are interrelated.
Clinical consensus criteria defined three variants
according to the presenting symptoms: progressive
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behavioral changes in the behavioral variant of FTD
(bvFTD), and prominent linguistic impairment in
agrammatic (nonfluent/agrammatic primary progres-
sive aphasia, PNFA) and semantic variants [1, 2]. The
definite diagnosis is based on three major pathological
subtypes of frontotemporal lobar degeneration (FTLD)
characterized by the presence of TDP43 (FTLD-
TDP), tau (FTLD-tau), or FUS-positive neuronal
inclusions [3].
Thirty percent of FTD patients have a positive fam-
ily history of the disease with an autosomal dominant
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inheritance. Mutations in the SQSTM1 gene, coding
for the p62 (sequestosome 1) protein, were initially
identified as a cause of Paget’s disease of bone (PDB)
and, recently, as a cause of familial amyotrophic lateral
sclerosis (ALS) [4]. More recently, SQSTM1 mutations
were also identified in few families with autosomal
dominant bvFTD [5, 6]. We described here a new clin-
ical phenotype associated to SQSTM1 mutation.
PATIENTS AND METHODS
Patients
A French family has been studied (Fig. 1). Three
siblings developed FTD at age ranging from 70 to 75
(patients 007, 008, 009). Their parents died at the age of
58 and 44 without known neurological disease. Family
history was censored in both parental branches.
Molecular analyses
Blood samples of the three patients (007, 008, 009)
were obtained; all participants signed an informed
consent for genetic studies. This study was approved
by the local research Ethics Committee (Ethics Com-
mittee from Assistance-Publique Hoˆpitaux de Paris).
DNA was extracted from blood samples. Muta-
tions in known FTD (C9ORF72, MAPT, PGRN,
VCP, CHMP2B) and ALS genes (SOD1, TARDBP,
FUS/TLS, PFN1, UBQLN2, hnRNPA2/B1, hnRNPA1,
MATR3) were initially excluded by Sanger sequenc-
ing or by repeat-primed PCR (for C9ORF72). The
whole exome was sequenced on DNA samples of
the three patients. Briefly, genomic DNA of patients
was prepared according to Illumina’s TruSeq Sample
Preparation v3 (Illumina, CA, USA) and sequence cap-
ture, enrichment, and elution was performed according
Fig. 1. Pedigree. The individuals are represented by diamonds for
confidentiality. Black diamonds: FTD; white diamonds: non symp-
tomatic individuals. Individuals 0007, 008, and 009 carried the
c.714 716delGAA mutation.
to manufacturer’s protocols (Illumina’s TruSeq Exome
Enrichment). Sequencing was performed on Illumina’s
HiSeq2000 using 100 bp paired-end reads. Sequence
alignment and variant calling was performed against
the reference human genome (UCSC hg19) using bwa
and the Genome Analysis Toolkit. Polymorphisms
found in the public databases and in 50 in-house
exomes of controls were excluded. Secondarily,
mutations identified in SQSTM1 gene were vali-
dated by Sanger sequencing according to previously
described methods [6]. The entire coding sequence
was also sequenced in 350 French age-matched healthy
controls.
RESULTS
Molecular analyses
A heterozygous mutation, c.714 716delGAA,
p.Lys238del, was identified in the exon 5 of SQSTM1
gene in the three affected siblings (007, 008, 009).
The mutation was validated by the Sanger method
in the three patients (Fig. 1). The Lys238 residue is
conserved across species. The mutation was previ-
ously identified as a disease-causing mutation in ALS
patients [4] and was predicted to be deleterious by
SIFT/PROVEAN in silico software (score: −11.7).
Furthermore, this mutation was absent from 350
French controls, from 6,503 individuals of the ‘exome
variant server’ (http://evs.gs.washington.edu/EVS/),
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/)
and 1000Genomes (http://www.1000genomes.org/)
databases, thus strongly supporting its deleterious
effect.
Clinical features
Patients’ neuropsychological scores are summa-
rized in Table 1.
Proband 007
This 77-year-old right-handed patient was evaluated
in our Department after two years of language diffi-
culty. He had endoprothetic treatment of the left hip
at 67 years old and a right femoral fracture at the age
of 75, without any obvious radiological or biological
signs of PDB. Examination showed apraxia of speech
characterized by an articulation planning deficit,
dysarthria with hypokinetic features and buccofacial
apraxia, associated with semantic and phonetic para-
phasia. Phonemic and semantic fluency sores were low
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Table 1
Neuropsychological scores of the patients
Patient 007 Patient 008 Patient 009
Age at evaluation, y 77 82 71 79 74 76
Disease duration, y 2 7 1 9 2 4
MMS/30 23 14 24 24 18 11
FCSRT
Encoding/16 12* 13* 16 13* 14* NA
Free recall 1,2,3/16 5/6/7 4/3/4* 6/9/9 6/7/8 5/5/9 NA
Cued recall 1,2,3/16 11/10/9 6/12/8 10/7/7 6/7/8 10/10/7 NA
Total recall/48 48 37* 48 42 46 NA
Recognition/16 16 16 16 16 16 NA
Delayed total recall 15 NA NA 16 15 NA
Rey figure Copy/36 NA NA 19 NA 17 18
Oral confrontation naming/80 69* 61* 80 73 75 73
Verbal fluency 2’
P letter 12* NA 23 20 10* 9*
Animals 2* NA 20 30 6* 4*
Frontal Assessment Battery/18 5* 5* 15* 16 9* 3*
Wisconsin Card Sorting Test
Criteria/6 1* NA 2* 2* NA NA
Errors 21* NA 20* 13* NA NA
Perseverations 3* NA 9* 5* NA NA
TMT A NA NA C0.75 C50 - 0.75 C0.75 C0.75
TMT B NA NA Impossible* Impossible* Impossible* Impossible*
MMS, Mini Mental Score; FCSRT, Free and Cued Selective Recall Reminding Test; TMT, Trail Making Test; NA: not available,*abnormal
value.
(respectively 12 and 2 words in two minutes). Syntac-
tic and single-word comprehensions were spared. Mild
grammatical deficit appeared in his spoken picture
description and in writing. Neuropsychological testing
showed executive dysfunction associated with severe
visuo-constructional impairment when copying the
Rey figure but preservation of memory (Fig. 2, Table 1).
Careful interview of the patient’s caregiver revealed
the absence of behavioral disorders. Deep tendon
reflexes were increase in all limbs and plantar reflex
was flexor bilaterally. He had no motor symptoms, no
gaze limitation, and no parkinsonian signs. Brain mag-
netic resonance imaging (MRI) showed major diffuse
cortical atrophy more marked on the frontal and tem-
poral lobes. ECD single photon emission computed
tomography (SPECT) of the brain revealed severe
hypoperfusion of frontal and temporal lobes, predomi-
nantly on the right side, and hypoperfusion of basal
ganglia (Fig. 3). Five years later, the patient dis-
played severe phonetic disintegration with worsening
of agrammatism but comprehension was spared. There
were no clinical or electromyographic signs of ALS.
Sibling 008
This 71-year-old right-handed patient developed
apragmatism over several months, without others
behavioral troubles. On initial examination, he had
a moderate dysarthria due to buccofacial apraxia.
There were no signs of upper or lower motor
neurons dysfunctions. Neuropsychological testing
showed executive dysfunction associated with visuo-
constructional deficit, without aphasia. Brain MRI
showed major diffuse atrophy more prominent on
the frontal and parietal lobes. Brain SPECT revealed
severe hypoperfusion of frontal and parietal lobes, par-
ticularly in bilateral sulcus centralis (Fig. 3). Eight
years after the disease onset, the clinical features were
highly consistent with apraxia of speech associated
with visuo-constructional deficit. Executive functions
also deteriorated (Table 1), but autonomy was still pre-
served with an overall slow progression.
Sibling 009
This 74-year-old right-handed patient presented
with visual and auditory hallucinations by the age of
72. He had bilateral hip fractures at the age of 67 caused
by falls, but had no obvious clinical, biological, or radi-
ological signs of PDB. Neurological examination was
normal. Neuropsychological testing showed preserved
memory functions with severe executive syndrome
and visuo-constructional disabilities (Fig. 2). CT scan
showed bilateral frontal atrophy. Brain ECD-SPECT
revealed cortical frontal and temporal hypoperfusion
(Fig. 3). Severe behavioral disorders subsequently
appeared, especially self-mutilation that required hand
amputation. Cognitive deficit worsened over time lead-
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Fig. 2. Copy of Rey figure of the patients carrying SQSTM1 mutations
Fig. 3. Brain imaging. ECD-SPECT (top) and brain MRI (coronal and axial sections, bottom) of patients 007, 008, and 009.
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ing to the diagnosis of bvFTD. The patient was finally
institutionalized and died at 80 years.
DISCUSSION
We describe a new family carrying a heterozygous
p.Lys238del mutation in SQSTM1 gene segregating
with FTD. This study further demonstrates the impli-
cation of SQSTM1 in FTLD spectrum of diseases.
Clinically, the three patients of the family were affected
by atypical forms of FTD. Two patients had hip and
femoral fractures, but none presented severe bone
symptoms and deformations. The patients were not
investigated specifically with biological testing or bone
scintigraphy but no radiological signs of PDB were
present on radiography. Furthermore, although the
p.Lys238del mutation has been previously identified in
ALS patients [4], motor neuron symptoms were absent
in the three patients. ALS patients are often not tested
for FTD symptoms, which could be the case for the
ALS patient with the same mutation. This family thus
illustrates the variability of bone and motor phenotype
that can be moderate or absent in SQSTM1 families. We
propose that SQSTM1 gene should be integrated in the
‘multisystem proteinopathies’ (MSP4), an emerging
group of genetic diseases clinically characterized by
variable association of FTD, ALS, PDB, and myopa-
thy, and so far including VCP (MSP1), hnRNPA2/B1
(MSP2), and hnNPA2 genes (MSP3) [7].
The three patients exhibited a similar neuropsycho-
logical profile associating dysexecutive syndrome and
early visuo-constructional disabilities. The episodic
memory was for a long time preserved. The patients
were mainly apathetic and one initially presented
psychotic symptoms with hallucinations at onset.
Brain imaging showed major opercular and perisylvian
involvement. None of the three patients completely fit
with the clinical criteria of bvFTD of Rascovsky [2]
at onset. Patient 009 was the only one to fulfil these
criteria after several years of evolution.
More interestingly, patient 007 presented apraxia
of speech, with buccofacial apraxia dysarthria and
anomia at onset. The patient 008 also had moderate
symptoms of apraxia of speech. Apraxia of speech
can be the initial sign of PNFA [2]. However, even if
two patients presented with language problems, both
of them presented early visuo-constructional disorders
and, therefore, do not completely fit with the diagnosis
of primary progressive aphasia according to the crite-
ria of Gorno-Tempini et al. [2, 8]. They also showed
different neuroimaging patterns, and neither of them
presents the typical neuroimaging of nfv-PPA [2, 8].
Many genetic cases of FTD do not present with the
typical features of sporadic FTD, or do not strictly meet
the criteria for any of the clinical variants. Notably, in
previous studies, all FTD patients carrying SQSTM1
mutations presented a behavioral variant of FTD [5, 6].
This family demonstrates that the phenotypes associ-
ated with SQTM1 mutations are more heterogeneous,
and that this gene should also be studied in patients
presenting with speech apraxia or behavioral disor-
ders associated with visuo-constructive deficit at onset,
even in absence of PDB or ALS.
Predicting the underlying pathology in patients with
FTD is difficult but will be particularly important
for future treatments targeting tau or TDP-43 pro-
teins. A pathological study previously showed that
SQSTM1 mutation carriers had TDP-43 and p62-
immunoreactive neuronal inclusions in the prefrontal
cortex [9]. So far, PNFA and more precisely, apraxia of
speech, was rather considered predictive of FTLD-tau
[10–12]. Our study supports a possible link between
speech apraxia and FTLD-TDP. This finding is sup-
ported by a recent pathological study in 11 patients
showing that nonfluent/agrammatic primary progres-
sive aphasia could be associated with FTLD-TDP
pathology [13].
In conclusion, our report widens the phenotypic
spectrum of SQSTM1 mutations, and further illustrates
the variability of phenotypes associated with SQSTM1
mutations thus supporting a pleiotropic effect of the
mutations.
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